Steven C Highfill, 70233 Highwood Ave, Ridgewood, NJ 07450

2022019, Jun 23, 2022

Sep 1, 2021

17/464528

- Basel, CH
- Philadelphia PA, US
Barbara Brannetti - Cambridge MA, US
Jennifer Brogdon - Sudbury MA, US
Naveen Kumar Dakappagari - Carlsbad CA, US
Saar Gill - Philadelphia PA, US
Steven Highfill - Bethesda MD, US
Lu Huang - West Roxbury MA, US
Carl H. June - Merion Station PA, US
Ju Young Kim - Carlsbad CA, US
Ming Lei - Acton MA, US
Na Li - Cambridge MA, US
Andreas Loew - Boston MA, US
Elena Orlando - Somerville MA, US
Marco Ruella - Ardmore PA, US
Thai Tran - Carlsbad CA, US
Jimin Zhang - Chestnut Hill MA, US
Li Zhou - Cambridge MA, US

C07K 14/705
C07K 14/725
C07K 16/28
A61K 45/06
A61K 39/00

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

2019029, Sep 26, 2019

Jan 24, 2019

16/256731

- Basel, CH
- Philadelphia PA, US
Barbara Brannetti - Cambridge MA, US
Jennifer Brogdon - Sudbury MA, US
Naveen Kumar Dakappagari - Carlsbad CA, US
Saar Gill - Philadelphia PA, US
Steven Highfill - Bethesda MD, US
Lu Huang - Cambridge MA, US
Carl H. June - Merion Station PA, US
Ju Young Kim - Carlsbad CA, US
Ming Lei - Acton MA, US
Na Li - Cambridge MA, US
Andreas Loew - Boston MA, US
Elena Orlando - Somerville MA, US
Marco Ruella - Ardmore PA, US
Thai Tran - Carlsbad CA, US
Jimin Zhang - Chestnut Hill MA, US
Li Zhou - Cambridge MA, US

C07K 14/705
A61K 39/00
C07K 16/28
C07K 14/725
A61K 45/06

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

2016036, Dec 15, 2016

Apr 8, 2016

15/094674

Hans Bitter - Cambridge MA, US
Jennifer Mary Bordeaux - Carlsbad CA, US
Barbara Brannetti - Basel, CH
Jennifer Brogdon - Cambridge MA, US
Naveen Kumar Dakappagari - Carlsbad CA, US
Saar Gill - Philadelphia PA, US
Steven Highfill - Bethesda MD, US
Lu Huang - Cambridge MA, US
Carl H. June - Merion Station PA, US
Ju Young Kim - Carlsbad CA, US
Ming Lei - Cambridge MA, US
Na Li - Cambridge MA, US
Andreas Loew - Cambridge MA, US
Elena Orlando - Cambridge MA, US
Marco Ruella - Philadelphia PA, US
Thai Tran - Carlsbad CA, US
Jimin Zhang - Cambridge MA, US
Li Zhou - Cambridge MA, US

C07K 14/705
A61K 39/00

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.